^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IFN stimulant

    Related drugs:
    4ms
    CONNECT: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov)
    P3, N=156, Completed, Biogen | Active, not recruiting --> Completed
    Trial completion
    7ms
    First in Human Study of T3P-Y058-739 (T3P) (clinicaltrials.gov)
    P1/2, N=100, Recruiting, T3 Pharmaceuticals AG | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    9ms
    Study of rSIFN-co for Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=7, Terminated, Sichuan Huiyang Life Science and Technology Corporation | N=36 --> 7 | Trial completion date: Dec 2027 --> Nov 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Nov 2024; Protocol has been amended and the Protocol amendment of Phase II was approved by the US FDA on Nov 2024 through SN0028.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    9ms
    rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 (clinicaltrials.gov)
    P2, N=188, Completed, Sichuan Huiyang Life Science and Technology Corporation | Active, not recruiting --> Completed
    Trial completion
    10ms
    Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women (clinicaltrials.gov)
    P1, N=20, Recruiting, BlueSky Immunotherapies GmbH | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    10ms
    BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects (clinicaltrials.gov)
    P=N/A, N=25, Completed, BlueSky Immunotherapies GmbH | Enrolling by invitation --> Completed | N=200 --> 25
    Trial completion • Enrollment change
    1year
    Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, BlueSky Immunotherapies GmbH
    New P1 trial
    over1year
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov)
    P3, N=142, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2024 --> May 2027
    Enrollment closed • Trial primary completion date
    over1year
    BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects (clinicaltrials.gov)
    P=N/A, N=200, Enrolling by invitation, BlueSky Immunotherapies GmbH | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    over1year
    INFORM: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (clinicaltrials.gov)
    P=N/A, N=4, Active, not recruiting, Bayer | Not yet recruiting --> Active, not recruiting | N=100 --> 4 | Initiation date: Sep 2024 --> Mar 2024
    Enrollment closed • Enrollment change • Trial initiation date
    over1year
    TLV-0326-24: Early Interferon-beta Treatment for West-Nile Virus Infection (clinicaltrials.gov)
    P2, N=100, Recruiting, Tel-Aviv Sourasky Medical Center
    New P2 trial
    over1year
    Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Fred Hutchinson Cancer Center | N=24 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    cyclophosphamide